Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.
For years, researchers have been moving towards decentralized clinical trials (DCTs), and in a matter of months, COVID-19 changed the trajectory. Clinical operations teams and investigator sites around the world rose to the challenge and worked quickly to deploy new tactics to serve their study participants. The resulting reward is that DCTs, which can be leveraged smartly to reduce participant burden and improve recruitment and retention, are now becoming more widely adopted in design considerations. But rewards bring about new risks and challenges, and DCTs create new concerns for monitoring participant safety. Dario Lirio – Senior Director, LifeSphere Clinical at ArisGlobal – analyzes the risks and rewards of DCTs.
Heart to Heart International (HHI), a global humanitarian organization focused on improving access to health, announced a partnership with Intouch Group, an EVERSANA Company, to support improvements to community health clinics in both Kansas City and Chicago.
Arcadia, a leading data analytics platform for healthcare and life sciences, and Datavant, a leader in helping organizations securely connect health data, announced a partnership to enable de-identified connectivity of Arcadia’s electronic health record data for life sciences research and commercial analytics.
Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”
As real world evidence (RWE) becomes a more prevalent resource for confirming and expanding product benefit-risk profiles, non-randomized studies (NRS) are emerging as a valuable generator of real world data (RWD). Joan Largent – Senior Director, Epidemiology and Outcomes Research at IQVIA – discusses the findings of her recent study and how researchers can utilize assessment tools for their ability to accurately assess NRS validity.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth, a leading telehealth and virtual prescribing platform serving life sciences companies, announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies worldwide.
AbbVie company Allergan Aesthetics announced the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, marks 20 years since the U.S. Food and Drug Administration first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.
On the heels of the Point of Care Marketing Association’s 2022 Industry Summit and in partnership with leading medical market research company MedSurvey, Havas Media Group (HMG) revealed findings from a new research study examining the matrix of influence surrounding prescribing drugs for patients. The findings identify who beyond MDs exerts influence over prescribing decisions, as well as the concerns, behaviors, trigger moments, and media habits of these influencers.
Kythera Labs, a leading data science platform provider for healthcare, announced financing led by Espresso Capital and advised by Brentwood Capital Advisors to support unprecedented growth and enhance its current offerings.